BiotechTube

Avelumab and Pepinemab

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Pancreatic Adenocarcinoma

Conditions

Metastatic Pancreatic Adenocarcinoma

Trial Timeline

Dec 10, 2022 → Dec 31, 2028

NCT ID
NCT05102721

About Avelumab and Pepinemab

Avelumab and Pepinemab is a phase 1/2 stage product being developed by Vaccinex for Metastatic Pancreatic Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05102721. Target conditions include Metastatic Pancreatic Adenocarcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05102721Phase 1/2Active

Competing Products

20 competing products in Metastatic Pancreatic Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Vaccinex

VX15/2503 + PlaceboPhase 2
44
Pepinemab + PlaceboPhase 1/2
33
VX15/2503 + PlaceboPhase 1
25
Dendritic Cell (DC1) Vaccine + Trastuzumab + Pepinemab + T-Cell therapyPhase 1
25
VX15/2503Phase 1
25